ArticleJournal of translational medicine2024
Serum matrix metalloproteinase-7 for discriminating biliary atresia: a diagnostic accuracy and validation study.
Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Serum matrix metalloproteinase-7 (MMP-7) as a Biomarker for differentiating biliary atresia from neonatal hepatitis: evidence synthesis through systematic review and meta-analysis.Pediatric surgery international · 2025Pooled it
- Effect of serum MMP-7 on the diagnostic accuracy of biliary atresia: systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Comparison of non-invasive liver fibrosis indicators for biliary atresia.Pediatric surgery international · 2026Article
- A comprehensive diagnostic model based on serum MMP-7: a convenient and efficient early diagnostic method for biliary atresia.BMC pediatrics · 2026Article
- Measuring MMP-7 levels in dried blood spots appears not feasible for newborn screening of biliary atresia.Hepatology communications · 2026Article
- Serum matrix metalloproteinase-7 as a diagnostic and prognostic biomarker in primary biliary cholangitis.Frontiers in medicine · 2026Article
- Comparison of preoperative serum MMP-7 to liver two-dimensional shear wave elastography and its integration into a novel nomogram for predicting the native liver survival of infants with biliary atresia.Quantitative imaging in medicine and surgery · 2026Article
- Biliary atresia-related liver fibrosis.Frontiers in cell and developmental biology · 2026Review
- Development and validation of a minimally invasive diagnostic model for biliary atresia using artificial intelligence.World journal of pediatrics : WJP · 2025Article
- Evaluating the role of Kasai portoenterostomy in biliary atresia older than 90 days.Pediatric surgery international · 2025Article
- Natural progression and prediction markers in non-clinically significant oesophageal varices in children.Journal of pediatric gastroenterology and nutrition · 2025Article
- A Scoring System Based on Diffusion Tensor Imaging and Blood Biochemistry Tests for Diagnosing Biliary Atresia in Infants.Children (Basel, Switzerland) · 2025Article
- 25OH vitamin D3 in biliary atresia: a simple and under-utilised diagnostic method.Frontiers in pediatrics · 2025Article
- Biliary Atresia: advances and challenges in early diagnosis and management.Jornal de pediatriaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrompt and precise differential diagnosis of biliary atresia (BA) among cholestatic patients is of great importance. Matrix metalloproteinase-7 (MMP-7) holds great promise as a diagnostic marker for BA. This study aimed to investigate the accuracy of age-specific serum MMP-7 for discriminating BA from other cholestatic pediatric patients.
methodsThis was a single center diagnostic accuracy and validation study including both retrospective and prospective cohorts. Serum MMP-7 concentrations were measured using an ELISA kit, the trajectory of which with age was investigated in a healthy infants cohort aged 0 to 365 days without hepatobiliary diseases (n = 284). Clinical BA diagnosis was based on intraoperative cholangiography and subsequent histological examinations. The diagnostic accuracy of age-specific cutoffs of serum MMP-7 were assessed in a retrospective cohort of cholestatic patients (n = 318, with 172 BA) and validated in a prospective cohort (n = 687, including 395 BA).
resultsThe MMP-7 concentration declines non-linearly with age, showing higher levels in healthy neonates as well as higher cutoff value in neonatal cholestasis. The area under the ROC curve (AUROC) was 0.967 (95% confidence interval [CI]: 0.946-0.988) for the retrospective cohort, and the cutoff of 18 ng/mL yielded 93.0% (95%CI: 88.1-96.3%), 93.8% (95%CI: 88.6-97.1%), 94.7% (95%CI: 90.1-97.5%), and 91.9% (95%CI: 86.4-95.8%) for sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), respectively. The performance of MMP-7 was successfully validated in the larger prospective cohort, resulting in a diagnostic sensitivity of 95.9% (379/395; 95% CI: 93.5-97.7%), a specificity of 87.3% (255/292; 95% CI: 83.0-90.9%), a PPV of 91.1% (379/416; 95% CI: 87.9-93.7%), and a NPV of 94.1% (255/271; 95% CI: 90.6-96.6%), respectively. Besides, higher cutoff value of 28.1 ng/mL achieved the best sensitivity, specificity, PPV, and NPV for infants aged 0-30 days, which was 86.4% (95% CI: 75.0-94.0%), 95.5% (95% CI: 77.2-99.9%), 98.1% (95% CI: 89.7-100%), and 72.4% (95% CI: 52.8-87.3%), respectively.
conclusionsThe serum MMP-7 is accurate and reliable in differentiating BA from non-BA cholestasis, showing its potential application in the diagnostic algorithm for BA and significant role in the future research regarding pathogenesis of BA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.